Navigation Links
ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
Date:7/2/2010

MINNEAPOLIS, July 2 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD) today announced that it has commenced a tender offer to holders of certain outstanding warrants to provide additional consideration for the exercise of such warrants.  The warrants subject to the tender offer are 1,752,760 publicly traded warrants and 2,752,947 unregistered warrants to purchase common stock that were issued on January 12, 2009 and will expire on January 7, 2014.  Also subject to the tender offer are 1,244,829 publicly traded warrants to purchase common stock that were issued on November 12, 2009 and will expire on November 12, 2012.  The tender offer commenced on Friday, July 2, 2010.

ProUroCare is offering to holders of the subject warrants the opportunity to exercise their existing warrants and receive, in addition to the shares of common stock purchased upon exercise, new, three-year replacement warrants.  The replacement warrants will have an exercise price of $1.30 per share and will be redeemable at ProUroCare's discretion at any time after the last sales price of its common stock equals or exceeds $4.00 for ten consecutive trading days.  ProUroCare must provide 30 days' prior written notice of a decision to redeem either the existing or replacement warrants.  Warrants not exercised during this 30-day period will be redeemed at $0.01 per warrant.  The purpose of the offer is to provide an incentive to exercise the subject warrants and thereby raise additional capital for ProUroCare.  

The offer is scheduled to expire at 4:00 P.M. Central Time on August 2, 2010, unless ProUroCare elects to extend the offer.  Subject warrants that are not tendered will retain their original terms including the $1.30 exercise price, expiration date and redemption terms.  Warrant holders may withdraw any tendered warrants before the expiration of the offer period and retain them on their original terms.  The subject warrants issued on January 12, 2009 may be redeemed at any time prior to expiration by ProUroCare.  The subject warrants issued on November 12, 2009 will be redeemable at ProUroCare's discretion at any time after the last sales price of its common stock equals or exceeds $4.00 for ten consecutive trading days.

The Offer Letter/Prospectus will be received by subject warrant holders in the near future (except for those who reside in states where the offer is not permitted).  For questions or assistance, or to request additional copies of the Offer Letter/Prospectus, which will be provided at ProUroCare's expense, warrant holders should contact Dick Thon, ProUroCare Medical, Inc., 6440 Flying Cloud Dr., Suite 101, Eden Prairie, MN 55344, (952) 698-1161.

About ProUroCare Medical, Inc.

ProUroCare Medical, Inc. is a publicly traded company engaged in the business of developing innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is used to document abnormalities of the prostate detected by a Digital Rectal Exam (DRE).  Based in Minneapolis, Minn., ProUroCare's common stock is quoted on the OTCBB.

ProUroCare Medical, Inc. has filed a Registration Statement on Form S-4 (including a prospectus) and a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission (the "SEC") for the tender offer and offering to which this communication relates. Before you accept the offer, you should read the Offer Letter/Prospectus in that registration statement, the related Letter of Transmittal, the Schedule TO and other documents ProUroCare has filed with the SEC, as well as any amendments or supplements thereto, for more complete information about ProUroCare, the tender offer and the offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.  Alternatively, ProUroCare will arrange to send you the Offer Letter/Prospectus and related documents, the Registration Statement on Form S-4 or the Tender Offer Statement on Schedule TO upon request by contacting Dick Thon, ProUroCare Medical, Inc., 6440 Flying Cloud Dr., Suite 101, Eden Prairie, MN 55344, (952) 698-1161. There shall there be no sales of the warrants or underlying common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.   


'/>"/>
SOURCE ProUroCare Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ProUroCare Medical Secures $885,000 in Financing
2. ProUroCare to Showcase Investigational Portable Platform for Its Prostate Imaging Device at AUA 2010
3. ProUroCare Medical Announces Filing of Request to Classify the Prostate Mechanical Imager ("PMI") as a Class II Device
4. ProUroCare Medical Elects Two New Directors
5. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
6. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
7. ProUroCare Medical Inc. Announces Pricing of Equity Offering
8. China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
9. Seniors and People with Disabilities Will Pay Steep Price for Medicares Competitive Bidding Program for Home Medical Equipment
10. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
11. Concord Medical Announces Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):